Literature DB >> 20009889

The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study.

Masashi Takano1, Toru Sugiyama, Nobuo Yaegashi, Mitsuaki Suzuki, Hiroshi Tsuda, Satoru Sagae, Yasuhiro Udagawa, Kazuo Kuzuya, Junzo Kigawa, Satoshi Takeuchi, Hitoshi Tsuda, Takuya Moriya, Yoshihiro Kikuchi.   

Abstract

Pure-type clear cell carcinoma (CCC) has been recognized as a distinct subtype of ovarian cancer, showing resistance to conventional platinum-based chemotherapy and resulting in poor prognosis. The aim of the study was to evaluate the effects of complete surgical staging procedures for early-stage CCC patients in a retrospective multi-institutional analysis. During the period 1992 to 2002, a total of 199 patients with pT1 M0 CCC were identified. Survival analysis was estimated by Kaplan-Meier methods, and prognostic factors were evaluated using a Cox regression model. Among pT1 M0 tumors, retroperitoneal lymph node status was negative in 125 cases (pN0, 63%), positive in 10 cases (pN1, 5%), and unknown in 64 cases (pNx, 32%). Progression-free survival of pN1 was significantly worse than that of pN0 (P < 0.05), whereas there was no significant difference between pN1 and pNx. There was no significant difference of overall survival (OS) among the 3 groups. Multivariate analysis revealed that peritoneal cytology status was the only independent prognostic factor for progression-free survival (P = 0.04), but completion of surgical staging procedures was not a prognostic factor. There was no significant prognostic factor for OS. Our study implied that complete surgical staging enabled us to distinguish a high-risk group of recurrence in pT1 M0 CCC; however, the procedure could not improve OS. Although the study was a limited retrospective study, the impact of peritoneal cytology status was more important than complete surgical staging procedure in CCC patients. More effective treatment modality was warranted, especially for CCC cases positive for malignant peritoneal cytology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20009889     DOI: 10.1111/IGC.0b013e3181a83f4f

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  10 in total

Review 1.  Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma.

Authors:  Kazuaki Takahashi; Masataka Takenaka; Ayako Kawabata; Nozomu Yanaihara; Aikou Okamoto
Journal:  Int J Clin Oncol       Date:  2020-01-27       Impact factor: 3.402

2.  Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinoma.

Authors:  Yuji Takei; Suzuyo Takahashi; Shizuo Machida; Akiyo Taneichi; Takahiro Yoshiba; Yoshifumi Takahashi; Chikako Yoshida; Yasushi Saga; Shigeki Matsubara; Hiroyuki Fujiwara
Journal:  Int J Clin Oncol       Date:  2018-04-20       Impact factor: 3.402

3.  Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers.

Authors:  K D Swenerton; J L Santos; C B Gilks; M Köbel; P J Hoskins; F Wong; N D Le
Journal:  Ann Oncol       Date:  2010-08-06       Impact factor: 32.976

4.  JAK2/STAT3 pathway as a therapeutic target in ovarian cancers.

Authors:  Tomoyuki Yoshikawa; Morikazu Miyamoto; Tadashi Aoyama; Hiroaki Soyama; Tomoko Goto; Junko Hirata; Ayako Suzuki; Isao Nagaoka; Hitoshi Tsuda; Kenichi Furuya; Masashi Takano
Journal:  Oncol Lett       Date:  2018-02-12       Impact factor: 2.967

5.  Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary.

Authors:  Jennifer J Mueller; Marie Holzapfel; Chan H Han; Kevin Santos; Camille Gunderson; Kathleen Moore; Britt Erickson; Charles A Leath; Elena Diaz; Christine Walsh; Stephanie L Wethington; Sheila Z Dejbakhsh; Richard R Barakat; Ginger J Gardner; David M Hyman; Robert A Soslow; Mario M Leitao
Journal:  Int J Gynecol Cancer       Date:  2016-01       Impact factor: 3.437

6.  Differential roles of the Wip1-p38-p53 DNA damage response pathway in early/advanced-stage ovarian clear cell carcinomas.

Authors:  Chenyang Xu; Takeo Minaguchi; Nan Qi; Kaoru Fujieda; Asami Suto; Hiroya Itagaki; Ayumi Shikama; Nobutaka Tasaka; Azusa Akiyama; Sari Nakao; Hiroyuki Ochi; Toyomi Satoh
Journal:  World J Surg Oncol       Date:  2022-04-30       Impact factor: 2.754

7.  A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology.

Authors:  Ming Chen; Ying Jin; Yalan Bi; Jie Yin; Yongxue Wang; Lingya Pan
Journal:  Onco Targets Ther       Date:  2014-10-16       Impact factor: 4.147

8.  Therapeutic significance of full lymphadenectomy in early-stage ovarian clear cell carcinoma.

Authors:  Hiroyuki Yamazaki; Yukiharu Todo; Chisa Shimada; Sho Takeshita; Shinichiro Minobe; Kazuhira Okamoto; Katsushige Yamashiro; Hidenori Kato
Journal:  J Gynecol Oncol       Date:  2017-12-11       Impact factor: 4.401

9.  Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review.

Authors:  Morikazu Miyamoto; Masashi Takano; Tomoko Goto; Masafumi Kato; Naoki Sasaki; Hitoshi Tsuda; Kenichi Furuya
Journal:  J Gynecol Oncol       Date:  2013-01-08       Impact factor: 4.401

10.  Omission of adjuvant therapy in stage I clear cell ovarian cancer: Review of the BC Cancer experience.

Authors:  Shiru L Liu; Anna V Tinker
Journal:  Gynecol Oncol Rep       Date:  2019-12-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.